Results for tag: "Choroideremia Drug"

Choroideremia is a rare, inherited disorder that affects the eyes. It is caused by a mutation in the CHM gene, which leads to progressive vision loss. The Choroideremia Drug market is focused on developing treatments to slow or stop the progression of the disease. Currently, there are no approved treatments for Choroideremia, but there are several drugs in clinical trials. These drugs are designed to target the underlying cause of the disease, and may be able to slow or stop its progression. The Choroideremia Drug market is a relatively small market, but it is growing as more companies enter the space. Companies such as NightstaRx, ProQR Therapeutics, and GenSight Biologics are all developing treatments for Choroideremia. These companies are working to develop treatments that can slow or stop the progression of the disease, and improve the quality of life for those affected. Show Less Read more